Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.

Abstract: The invention provides a human Emr1-like G protein coupled receptor (EGPCR) and polynucleotides which identify and encode EGPCR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EGPCR.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P.sub.U2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.

Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG and for gpg antisense molecules. The invention also provides for purified GPG; antibodies, antagonists and inhibitors which specifically bind GPG; and pharmaceutical compositions and methods of treatment based on GPG antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences, or complements thereof, encoding GPG, purified GPG to be used as a positive control, and antibodies which specifically bind to GPG.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: The present invention provides a polynucleotide (snpg) initially isolated from a colon cDNA library which identifies and encodes a novel human synaptogyrin homolog (SNPG). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SNPG. The invention also provides for the use of SNPG in the membrane of a vesicle containing a chemical or biological therapeutic composition for the treatment of disease, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the abnormal or excess expression of SNPG. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of snpg, or anti-SNPG antibodies which specifically bind to the polypeptide, SNPG.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (CB). The present invention also provides for antisense molecules to the nucleotide sequences which encode CB, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.

Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG. The invention also provides for purified GPG.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cb, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for the detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.